Nurix Therapeutics is positioned for a breakthrough in CLL with NX-5948, demonstrating strong efficacy in post-Pirtobrutinib settings. Phase 1 data showed an 83% response rate at 600mg and 22.1 months ...
Zhongyao Ma, PhD, holds a bachelor’s degree in biology from Shanghai Jiao Tong University and a PhD in genetics and developmental biology from the University of Georgia, U.S. His research focused on ...
Company enters into new agreement with the Gates Foundation to identify novel drug leads targeting tuberculosis and malaria and new agents for non-hormonal contraception. CHENGDU, China, Nov. 20, 2025 ...
Charles River and X-Chem Announce Strategic Collaboration to Enhance Hit Identification Capabilities
WILMINGTON, Mass.--(BUSINESS WIRE)--$CRL #CDMO--Charles River Laboratories International, Inc. (NYSE:CRL) today announced a strategic collaboration with X-Chem, Inc ...
Charles River Laboratories International, entered a strategic collaboration with X-Chem, a pioneer in DNA-encoded library (DEL) technology and a data-driven drug discovery company, to enhance its hit ...
In this free webinar, gain insight into why the majority of DNA-encoded library (DEL) data has historically been ignored, and what is being missed. Attendees will learn how chemomic approaches ...
Despite the increasing popularity of targeted protein degradation as a therapeutic strategy, the majority of these drug discovery approach rely on just two E3 ligases, cereblon and VHL. The discovery ...
Baylor College of Medicine and Site Tx, Inc. are collaborating to develop novel small-molecule drugs that allow for the fine-tuning of immune responses in multiple disease. Focusing on small molecule ...
MONHEIM, Germany and Waltham, Mass. , Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cube Biotech, a pioneer in membrane protein stabilization and purification, and X-Chem, the global leader in DNA-Encoded Library ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results